Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

3.5K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.5K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

284
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
284
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

218
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
218
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K
Gene Duplication and Divergence02:37

Gene Duplication and Divergence

6.3K
The seminal work of Ohno in 1970 popularized the idea of gene duplication and divergence. DNA sequence comparison studies reveal that a large portion of the genes in bacteria, archaebacteria, and eukaryotes was  generated by gene duplication and divergence, indicating its critical role in evolution.
The duplicated copies of the gene are called Paralogs. Paralogs with similar sequences and functions form a gene family. Across several species, a large number of gene families are...
6.3K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

1.2K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Long-Term Human Liver Spheroid Model for Assessing Silencing and Durability of GalNAc-Conjugated siRNAs.

Clinical and translational science·2026
Same author

The evolving landscape of pharmacogenomics: Current achievements and future directions.

Pharmacological reviews·2026
Same author

Perceived stress four weeks after initiation of escitalopram monotherapy as a predictor of anxiolytic and antidepressant effects.

Journal of affective disorders·2026
Same author

Personal recovery as outcome measure in mental health research: A meta-analysis on the sensitivity to change properties of the Recovery Assessment Scale.

Journal of affective disorders·2026
Same author

Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.

NPJ genomic medicine·2026
Same author

Dietary-Driven Gene Expansion.

Clinical pharmacology and therapeutics·2025

Related Experiment Video

Updated: Sep 1, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.9K

Cytochrome P450 polymorphism: From evolution to clinical use.

Magnus Ingelman-Sundberg1

  • 1Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institute, Stockholm, Sweden.

Advances in Pharmacology (San Diego, Calif.)
|August 11, 2022
PubMed
Summary

Genetic diversity in drug-metabolizing enzymes, like cytochromes P450, aids survival but complicates personalized medicine. Further research is needed to link genetic variants to drug response and toxicity.

Keywords:
AlkaloidsCYP6CY3Genetic selectionGuidelinesMissing heritabilityPharmacogenomic biomarkersPharmacogenomics

More Related Videos

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

13.9K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K

Related Experiment Videos

Last Updated: Sep 1, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.9K
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

13.9K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K

Area of Science:

  • Biochemistry
  • Pharmacogenomics
  • Evolutionary Biology

Background:

  • Cytochromes P450 (CYPs) are crucial enzymes, divided into evolutionarily stable endogenous groups and diverse xenobiotic-metabolizing groups.
  • Genetic diversity in drug-metabolizing CYPs is driven by environmental factors and dietary selection, not conserved endogenous functions.
  • These genetic variations influence drug detoxification and survival in different environments.

Purpose of the Study:

  • To explore the evolutionary basis of genetic diversity in drug-metabolizing enzymes.
  • To highlight the potential of genetic variants as biomarkers for personalized medicine.
  • To address the challenges in correlating genotype with drug metabolism phenotype.

Main Methods:

  • Comparative analysis of CYP gene evolution and diversity.
  • Review of genetic polymorphisms related to environmental and dietary factors.
  • Examination of pharmacogenomic data and twin studies.

Main Results:

  • Extensive genetic diversity exists in xenobiotic-metabolizing CYPs, linked to environmental adaptation.
  • Gene duplication and amplification events observed under high dietary selection.
  • Genetic variants in drug-metabolizing enzymes show promise as pharmacogenomic labels for tailored drug therapy.

Conclusions:

  • Genetic polymorphisms in drug-metabolizing enzymes are key to personalized medicine, improving drug efficacy and reducing adverse reactions.
  • Despite advances, significant genetic variability remains undiscovered, hindering a complete genotype-phenotype correlation for drug metabolism.
  • Further research into genetic variants is essential for optimizing drug treatment and achieving true personalized medicine.